Colon & REctal




Each year in the United States more than 130,000 new colorectal cancers are diagnosed.

Colorectal cancer affects the large intestines.

This is the lower part of the digestive tract, the last several inches of which is known as the rectum.

This part of the digestive system plays a major role in helping the body absorb nutrients, minerals and water. In addition, the colon helps rid the body of solid waste.

Colon cancers begin as benign growths known as polyps.

Over a period of years these polyps progress to invasive malignancies.

In their early stages polyps can be found and removed before they pose a risk. Since they usually cause no symptoms, it is recommended that people have regular colonoscopy screenings beginning at age 50.

Certain genetic mutations can greatly increase the risk of developing colon cancer.

Among the most common are hereditary non-polyposis colon carcinoma (HNPCC) or Lynch Syndrome and the familial adenomatous polyposis syndrome (FAP).

However the majority of colorectal cancers occur in people with no known genetic risk factors. 


Between 90 and 95 percent of all colon cancers are adenocarcinomas.

More rare forms of colon cancer include: neuroendocrine, gastrointestinal stromal tumors (GISTs), lymphoma, melanoma and leiomyosarcoma.

Some of these types of cancers occur primarily in other parts of the body.

If your cancer is the most common form—adenocarcinoma—then your doctor will develop a treatment plan based on the stage of development.



The long standing use of occult blood tests (testing for microscopic or invisible blood in the stool) is now being replaced by molecular technologies that utilize stool samples to screen for genetic mutations associated with colon cancer.

The gold standard for diagnosis remains the colonoscopy. 

Current recommendations are for patients over the age of 50 to have a screening colonoscopy. 

If polyps are identified or the patient has a family history of colon cancer, then the test is repeated within 5 years.  Other techniques such as CT, colonography, and capsule colonoscopy can be employed.

Nonetheless, the colonoscopic approach provides the best option as it allows for the identification of abnormal lesions as well as biopsy for confirmation of diagnosis.


This staging of your cancer refers to how far it has spread beyond the location where it first developed.

The stages begin at 0 and go up to Stage IV—the higher the number, the further the cancer has advanced.

For example, Stage IV colon cancer represents a spread to other organs.

Patients with cancers that have not spread beyond the colon or to the lymph nodes generally do not require any form of postoperative therapy.

For those patients with more advanced disease post operative chemotherapy or radiation is required.



The types of treatments recommended will depend on the stage of your cancer.

The three primary colon cancer treatment options are surgery, radiation, and chemotherapy.

If your cancer is caught at an early stage it is probably confined to the polyp.

In this case, your doctor may be able to remove it completely during a colonoscopy.

If the pathology report confirms that cancer didn’t extend into the base of the polyp (where it attaches to the bowel wall) the likelihood of cure is very good following surgery.

Larger polyps and invasive cancers might also require chemotherapeutic intervention.

Currently, common treatment strategies are based upon standard chemotherapy protocols. For colorectal cancer patients the most widely used drugs are flourouracil (5-FU) plus leucovorin (FU/LV) and the closely related capecitabine.

The addition of irinotecan and oxaliplatin can often demonstrably improve the effect of 5-FU based therapy and capecitabine. Monoclonal antibodies like Erbitux, Vectibix and Avastin are also often used in combination with chemotherapy.

At Nagourney Cancer Institute, we recommend colon cancer treatment regimens based upon the observed patterns of cell death in your cancer cells following exposure to drugs in our laboratory.

As a colon or rectal cancer patient, you may be responsive to several different drugs or combinations.

Call us at 1-800-542-4357 or contact us via email so we can help you select the most effective and least toxic drug regimen for treating your cancer.

Doctor Using Digital Tablet

Schedule a Consultation

Nagourney Cancer Institute
750 E. 29th Street
Long Beach, California 90806

  • Facebook
  • YouTube
  • Instagram

Nagourney Cancer Insitute is managed by Rational Therapeutics, LLC.  EVA-PCD, Target Rx, and Translational Rx are registered trademarks of Rational Therapeutics.

2019 Nagourney Cancer Institute.  750 E. 29th Street, Long Beach, CA 90806   (800) 542-4357   All rights reserved.